Literature DB >> 22519405

Vascular endothelial growth factor secretion by nonmyocytes modulates Connexin-43 levels in cardiac organoids.

Rohin K Iyer1, Devang Odedra, Loraine L Y Chiu, Gordana Vunjak-Novakovic, Milica Radisic.   

Abstract

We previously showed that the sequential, but not simultaneous, culture of endothelial cells (ECs), fibroblasts (FBs), and cardiomyocytes (CMs) resulted in elongated, beating cardiac organoids. We hypothesized that the expression of Cx43 and contractile function are mediated by vascular endothelial growth factor (VEGF) released by nonmyocytes during the preculture period. Cardiac organoids (~200 μm diameter) were cultivated in microchannels to enable rapid screening. Three experimental groups were formed: (i) Simultaneous Preculture (ECs+FBs for 48 h, followed by CMs), (ii) Sequential Preculture (ECs for 24 h, FBs for 24 h, followed by CMs), and (iii) Simultaneous Triculture (ECs+FBs+CMs). Controls included CMs only, FBs only, and ECs only groups, and preculture with ECs only or FBs only. The highest VEGF levels were found in the Preculture groups [Simultaneous Preculture, 8.9±2.7 ng/(mL·h(-1)); Sequential Preculture, 16.6±3.4 ng/(mL·h(-1))], as compared with Simultaneous Triculture where VEGF was not detectable, as shown by enzyme-linked immunosorbent assay. Analytical flow cytometry showed that VEGFR2 was expressed by ECs (86%±2 VEGFR2+), FBs (44%±1 VEGFR2+), and CMs (49%±2 VEGFR2+), showing that all three cell types were capable of responding to changes in VEGF. Addition of anti-VEGF neutralizing IgG (0.4 μg/mL) to Simultaneous Preculture resulted in 3-fold decrease in Cx43 mRNA and 1.5-fold decrease in Cx43 protein, while Simultaneous Triculture supplemented with VEGF ligand (30 ng/mL) had a threefold increase in Cx43 mRNA and a twofold increase in Cx43 protein. Addition of a small molecule inhibitor of the VEGFR2 receptor (19.4 nM) to Sequential Preculture caused a 1.4-fold decrease in Cx43 mRNA and a 4.1-fold decrease in Cx43 protein. Cx43 was localized within CMs, and not within FBs or ECs. Enriched CM organoids and Sequential Preculture organoids grown in the presence of VEGFR2 inhibitor displayed low levels of Cx43 and poor functional properties. Taken together, these results suggest that endogenous VEGF-VEGFR2 signaling enhanced Cx43 expression and cardiac function in engineered cardiac organoids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22519405      PMCID: PMC3432907          DOI: 10.1089/ten.TEA.2011.0468

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  26 in total

1.  High-density seeding of myocyte cells for cardiac tissue engineering.

Authors:  Milica Radisic; Michelle Euloth; Liming Yang; Robert Langer; Lisa E Freed; Gordana Vunjak-Novakovic
Journal:  Biotechnol Bioeng       Date:  2003-05-20       Impact factor: 4.530

Review 2.  Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity.

Authors:  Dirk L Brutsaert
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

3.  Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin.

Authors:  Giedrius Gaudesius; Michele Miragoli; Stuart P Thomas; Stephan Rohr
Journal:  Circ Res       Date:  2003-07-31       Impact factor: 17.367

4.  Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration.

Authors:  Daria A Narmoneva; Rada Vukmirovic; Michael E Davis; Roger D Kamm; Richard T Lee
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

5.  Regulation of connexin 43 gene expression by cyclical mechanical stretch in neonatal rat cardiomyocytes.

Authors:  T L Wang; Y Z Tseng; H Chang
Journal:  Biochem Biophys Res Commun       Date:  2000-01-19       Impact factor: 3.575

6.  Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution.

Authors:  A C Nag
Journal:  Cytobios       Date:  1980

7.  Autocrine regulation of myocyte Cx43 expression by VEGF.

Authors:  Rhea C Pimentel; Kathryn A Yamada; André G Kléber; Jeffrey E Saffitz
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

Review 8.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.

Authors:  M Shibuya
Journal:  Cell Struct Funct       Date:  2001-02       Impact factor: 2.212

9.  Biofabrication enables efficient interrogation and optimization of sequential culture of endothelial cells, fibroblasts and cardiomyocytes for formation of vascular cords in cardiac tissue engineering.

Authors:  Rohin K Iyer; Loraine L Y Chiu; Gordana Vunjak-Novakovic; Milica Radisic
Journal:  Biofabrication       Date:  2012-07-31       Impact factor: 9.954

10.  Induction of endothelial cell differentiation in vitro by fibroblast-derived soluble factors.

Authors:  M Kuzuya; J L Kinsella
Journal:  Exp Cell Res       Date:  1994-12       Impact factor: 3.905

View more
  22 in total

1.  Design and formulation of functional pluripotent stem cell-derived cardiac microtissues.

Authors:  Nimalan Thavandiran; Nicole Dubois; Alexander Mikryukov; Stéphane Massé; Bogdan Beca; Craig A Simmons; Vikram S Deshpande; J Patrick McGarry; Christopher S Chen; Kumaraswamy Nanthakumar; Gordon M Keller; Milica Radisic; Peter W Zandstra
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-19       Impact factor: 11.205

2.  From Engineered Tissues and Microfludics to Human Eyes-On-A-Chip.

Authors:  Milica Radisic
Journal:  J Ocul Pharmacol Ther       Date:  2019-11-07       Impact factor: 2.671

3.  Modular design of a tissue engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Jinkyu Park; Christopher W Anderson; Lorenzo R Sewanan; Mehmet H Kural; Yan Huang; Jiesi Luo; Liqiong Gui; Muhammad Riaz; Colleen A Lopez; Ronald Ng; Subhash K Das; Juan Wang; Laura Niklason; Stuart G Campbell; Yibing Qyang
Journal:  Acta Biomater       Date:  2019-10-19       Impact factor: 8.947

Review 4.  Can We Engineer a Human Cardiac Patch for Therapy?

Authors:  Jianyi Zhang; Wuqiang Zhu; Milica Radisic; Gordana Vunjak-Novakovic
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

5.  Engineering microenvironment for human cardiac tissue assembly in heart-on-a-chip platform.

Authors:  Yimu Zhao; Naimeh Rafatian; Erika Y Wang; Nicole T Feric; Benjamin F L Lai; Ericka J Knee-Walden; Peter H Backx; Milica Radisic
Journal:  Matrix Biol       Date:  2019-04-11       Impact factor: 11.583

Review 6.  Biomaterial based cardiac tissue engineering and its applications.

Authors:  Locke Davenport Huyer; Miles Montgomery; Yimu Zhao; Yun Xiao; Genevieve Conant; Anastasia Korolj; Milica Radisic
Journal:  Biomed Mater       Date:  2015-05-20       Impact factor: 3.715

Review 7.  Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening.

Authors:  Yosuke K Kurokawa; Steven C George
Journal:  Adv Drug Deliv Rev       Date:  2015-07-23       Impact factor: 15.470

8.  Bioreactor for modulation of cardiac microtissue phenotype by combined static stretch and electrical stimulation.

Authors:  Jason W Miklas; Sara S Nunes; Aarash Sofla; Lewis A Reis; Aric Pahnke; Yun Xiao; Carol Laschinger; Milica Radisic
Journal:  Biofabrication       Date:  2014-05-30       Impact factor: 9.954

Review 9.  Generation of tissue constructs for cardiovascular regenerative medicine: from cell procurement to scaffold design.

Authors:  Vishal Tandon; Boyang Zhang; Milica Radisic; Shashi K Murthy
Journal:  Biotechnol Adv       Date:  2012-08-24       Impact factor: 14.227

10.  Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip.

Authors:  Yu Shrike Zhang; Andrea Arneri; Simone Bersini; Su-Ryon Shin; Kai Zhu; Zahra Goli-Malekabadi; Julio Aleman; Cristina Colosi; Fabio Busignani; Valeria Dell'Erba; Colin Bishop; Thomas Shupe; Danilo Demarchi; Matteo Moretti; Marco Rasponi; Mehmet Remzi Dokmeci; Anthony Atala; Ali Khademhosseini
Journal:  Biomaterials       Date:  2016-09-05       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.